ArticleFrontiers in immunology2020
High-Throughput
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Major Histocompatibility Complex Class I-Related Chain A (MICA) Allelic Variants Associate With Susceptibility and Prognosis of Gastric Cancer.Frontiers in immunology · 2021Trial
- Antibodies to Non-HLA Antigens and Their Role in Organ Transplant Rejection.International journal of immunogenetics · 2026Review
- A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.Cell reports. Medicine · 2026Article
- Advances inFrontiers in immunology · 2026Article
- HLA Class Ib and MICA/MICB Expression in Human Tissues and Cell Types: Reshuffling Immune Players.HLA · 2025Article
- Methodological approach for allele-specific antibody responses to HEK-293T-based cell lines expressing single MHC class I chain-related gene B antigens.BMC molecular and cell biology · 2025Article
- Article
- CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity.Journal for immunotherapy of cancer · 2025Article
- Post-translational modification of NK cell receptors offers clues to antigenic specificity riddle.Frontiers in immunology · 2025Review
- Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253.Annals of translational medicine · 2024Article
- MICA-specific nanobodies for diagnosis and immunotherapy of MICAFrontiers in immunology · 2024Article
- Observational
- Immune evasion by proteolytic shedding of natural killer group 2, member D ligands inFrontiers in immunology · 2024Article
- CLPTM1L is a GPI-anchoring pathway component targeted by HCMV.The Journal of cell biology · 2023Article
- A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.Med (New York, N.Y.) · 2023Article
- Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation.Blood advances · 2023Article
- High population frequencies ofFrontiers in immunology · 2023Article
- Impact of MICA 3'UTR allelic variability on miRNA binding prediction, a bioinformatic approach.Frontiers in genetics · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MICA and MICB are ligands of the NKG2D receptor and thereby influence NK and T cell activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.